Brokerages Anticipate INmune Bio, Inc. (NASDAQ:INMB) to Announce -$0.60 Earnings Per Share

Equities research analysts expect that INmune Bio, Inc. (NASDAQ:INMBGet Rating) will announce ($0.60) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for INmune Bio’s earnings. INmune Bio reported earnings per share of ($0.32) during the same quarter last year, which suggests a negative year over year growth rate of 87.5%. The company is scheduled to report its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that INmune Bio will report full year earnings of ($2.27) per share for the current year. For the next year, analysts expect that the firm will post earnings of ($3.12) per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that that provide coverage for INmune Bio.

INmune Bio (NASDAQ:INMBGet Rating) last released its quarterly earnings results on Thursday, March 3rd. The company reported ($0.55) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.03. During the same quarter in the prior year, the company posted ($0.24) EPS.

A number of research analysts have recently weighed in on INMB shares. B. Riley cut their price target on shares of INmune Bio from $32.00 to $20.00 and set a “buy” rating on the stock in a report on Monday, January 24th. Maxim Group reiterated a “buy” rating and issued a $22.00 target price on shares of INmune Bio in a report on Friday, March 4th. Finally, Zacks Investment Research upgraded shares of INmune Bio from a “strong sell” rating to a “hold” rating in a report on Thursday, March 10th.

Large investors have recently bought and sold shares of the company. Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of INmune Bio during the 3rd quarter worth about $31,000. Morgan Stanley boosted its position in shares of INmune Bio by 97.4% during the 1st quarter. Morgan Stanley now owns 3,093 shares of the company’s stock valued at $37,000 after acquiring an additional 1,526 shares in the last quarter. Bank of America Corp DE boosted its position in shares of INmune Bio by 109.5% during the 4th quarter. Bank of America Corp DE now owns 3,769 shares of the company’s stock valued at $38,000 after acquiring an additional 1,970 shares in the last quarter. Westside Investment Management Inc. acquired a new stake in shares of INmune Bio during the 4th quarter valued at about $79,000. Finally, Wells Fargo & Company MN boosted its position in shares of INmune Bio by 338.1% during the 4th quarter. Wells Fargo & Company MN now owns 11,509 shares of the company’s stock valued at $118,000 after acquiring an additional 8,882 shares in the last quarter. Institutional investors own 10.77% of the company’s stock.

Shares of INmune Bio stock traded down $0.32 during midday trading on Wednesday, reaching $7.99. 274 shares of the company’s stock traded hands, compared to its average volume of 146,596. The firm has a 50 day moving average of $8.62. The company has a current ratio of 18.95, a quick ratio of 18.95 and a debt-to-equity ratio of 0.18. INmune Bio has a 52 week low of $6.18 and a 52 week high of $30.37.

About INmune Bio (Get Rating)

INmune Bio, Inc, a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease.

Further Reading

Get a free copy of the Zacks research report on INmune Bio (INMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for INmune Bio (NASDAQ:INMB)

Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.